Active — Not RecruitingPhase 4

Study to Compare the Efficacy and Safety After Conversion to RaparoBell® or My-Rept® in Kidney Transplant Patients

South Korea206 participantsStarted 2021-11-19

Plain-language summary

The purpose of this study is to evaluate the efficacy and Safety after conversion to RaparoBell® or Myrept® in patients who in renal transplant patients undergoing maintenance therapy with Mycophenolic acid.

Who can participate

Age range20 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients who at least 1 year and less than 10 years after kidney transplantation
✓. Over 20 years old
✓. Patients on immunosuppressive maintenance therapy using combination of Calcineurin Inhibitor and Mycophenolic acid after kidney transplantation

Exclusion criteria

✕. Patients who have transplanted organs other than kidney
✕. At the time of Screening
✕. Patents who had a record of taking mTOR inhibitor before 3 months
✕. In investigator's judgement

What they're measuring

Incidence of composite efficacy failure

Timeframe: Until 24 weeks

Trial details

NCT IDNCT05193565

SponsorChong Kun Dang Pharmaceutical

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2026-07

View on ClinicalTrials.gov More Kidney Transplantation trials